Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-55
SponsorThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
About this trial
This clinical trial aims to evaluate the weight-loss efficacy and safety of efsubaglutide alfa in patients who remain obese 6 months after metabolic surgery.
Eligibility criteria
Qualifiers
6 months after metabolic surgery
18 years ≤ age ≤ 55 years
Body Mass Index (BMI) ≥ 28 kg/m²
Voluntarily sign the informed consent form and agree to strictly adhere to the requirements and restrictions outlined in the informed consent form and this protocol throughout the entire study period.
Disqualifiers
Subjects suspected by the investigator of having a potential allergy to the study drug or its components, or those with a history of allergic constitution;
Use of weight-loss medications within 3 months prior to screening or currently using such medications, e.g., sibutramine hydrochloride, orlistat, phentermine, etc.;
Participation in other clinical trials (receiving investigational drug treatment) within 3 months prior to screening.
History of depression; or history of severe psychiatric disorders such as schizophrenia, bipolar disorder, etc.;
Trial design
Treatments tested in this trial
- Efsubaglutide Alfa Injection
- Diet and exercise guidelines
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov